Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
This journal supports preprints as a means to rapidly share research, but discourages their use as stand-alone citations disclosing a new method integral to the key results in a paper.
Although Kymriah's approval represents a landmark for chimeric antigen receptor T-cell (CAR-T) therapy in B-cell malignancies, solid tumors remain a formidable challenge.
Funders need to pay more attention to research aimed at increasing the shelf life of human organs. Doing so could pay dividends for both transplantation and basic research.
Retraction of a study claiming gene editing via an Argonaute enzyme illustrates the importance of post-publication peer review in the age of 24/7 media.
Digital medicine's extraordinary ability to communicate with patients, especially in under-served communities, could help reorient the biotech industry to better address aging and its associated diseases.
RNA-based therapeutics are poised to become successful commercial products, but wide adoption across the biopharmaceutical industry will likely take a few more years.
Despite an increasingly strident outcry against drug prices in the United States, manufacturers likely face an evolution in the reimbursement landscape, rather than a revolution.
The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval.
Although a US law mandating disclosure of GM ingredients provides food companies with a way out of the labeling rabbit hole, appeasing the anti-GM movement will likely backfire.